These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7955800)

  • 1. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    Clin Pharmacol Ther; 1994 Oct; 56(4):389-97. PubMed ID: 7955800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    Int J Clin Pharmacol Ther; 1994 May; 32(5):223-30. PubMed ID: 7921515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tirilazad clearance by phenytoin.
    Fleishaker JC; Pearson LK; Peters GR
    Biopharm Drug Dispos; 1998 Mar; 19(2):91-6. PubMed ID: 9533108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital.
    Fleishaker JC; Pearson LK; Peters GR
    Eur J Clin Pharmacol; 1996; 50(1-2):139-45. PubMed ID: 8739825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    J Clin Pharmacol; 1994 Aug; 34(8):837-41. PubMed ID: 7962672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age and gender on tirilazad pharmacokinetics in humans.
    Hulst LK; Fleishaker JC; Peters GR; Harry JD; Wright DM; Ward P
    Clin Pharmacol Ther; 1994 Apr; 55(4):378-84. PubMed ID: 8162663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults.
    Fleishaker JC; Straw RN; Cross CJ
    J Pharm Sci; 1997 Apr; 86(4):434-7. PubMed ID: 9109044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad.
    Fleishaker JC; Peters GR
    J Clin Pharmacol; 1996 Sep; 36(9):809-13. PubMed ID: 8889901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.
    Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Peters GR
    J Pharmacol Exp Ther; 1996 May; 277(2):991-8. PubMed ID: 8627582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day.
    Fleishaker JC; Peters GR
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):28-32. PubMed ID: 9021439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
    Fleishaker JC; Pearson PG; Wienkers LC; Pearson LK; Moore TA; Peters GR
    J Pharmacol Exp Ther; 1998 Nov; 287(2):591-7. PubMed ID: 9808685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage.
    Fleishaker JC; Fiedler-Kelly J; Grasela TH
    Pharm Res; 1999 Apr; 16(4):575-83. PubMed ID: 10227715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis.
    Pearson LK; Fleishaker JC; Peters GR
    Eur J Clin Pharmacol; 1996; 50(4):299-304. PubMed ID: 8803523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration.
    Fleishaker JC; Peters GR; Cathcart KS
    J Clin Pharmacol; 1993 Feb; 33(2):175-81. PubMed ID: 8382708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration.
    Fleishaker JC; Peters GR; Cathcart KS; Steenwyk RC
    J Clin Pharmacol; 1993 Feb; 33(2):182-90. PubMed ID: 8440768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of endotoxin on tirilazad mesylate (U74006F) pharmacokinetic parameters in neonatal calves.
    Rose ML; Semrad SD; Putnam ML; Brown SA
    J Vet Pharmacol Ther; 1993 Dec; 16(4):438-45. PubMed ID: 8126760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat.
    Laizure SC; Franklin LK; Kaiser DG; Williams CL; Stevens RC; Sanders PL; Miller M
    Drug Metab Dispos; 1993; 21(5):951-4. PubMed ID: 7902261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylate.
    Fleishaker JC; Hulst LK; Peters GR
    Pharm Res; 1994 Feb; 11(2):341-4. PubMed ID: 8165199
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of tirilazad mesylate (U74006F) on cerebral oxygen consumption, and reactivity of cerebral blood flow to carbon dioxide in healthy volunteers.
    Olsen KS; Videbaek C; Agerlin N; Krøll M; Bøge-Rasmussen T; Paulson OB; Gjerris F
    Anesthesiology; 1993 Oct; 79(4):666-71. PubMed ID: 8214745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury.
    Smith SL; Scherch HM; Hall ED
    J Neurosurg; 1996 Feb; 84(2):229-33. PubMed ID: 8592225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.